A5084836760- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Screening and Detection
- Digestive system and related health
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Metabolism, Diabetes, and Cancer
- Gene expression and cancer classification
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Biosensing Techniques and Applications
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Advanced biosensing and bioanalysis techniques
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Cancer Cells and Metastasis
Vejle Sygehus
2017-2020
University of Southern Denmark
2018
Lillebaelt Hospital
2010-2018
Abstract Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including putative oncogene ciRS-7 (CDR1as), been proposed to function as competitive endogenous (ceRNAs) by sponging specific microRNAs. Here, we report first spatially resolved cellular expression patterns of colon and show that is completely absent cells, but highly expressed stromal cells within tumor microenvironment. Additionally, our data suggest this generally apply...
High-risk patients with stage II colon cancer (CC) may benefit from adjuvant chemotherapy, but additional prognostic markers are needed for better stratification. We investigated the value of tumour stroma ratio (TSR) and budding (TB).A nationwide population-based cohort 573 CC was included. TSR scored on hematoxylin eosin sections as low (> 50% stroma) high (≤ stroma). TB evaluated in hotspots pan-cytokeratin stained 10 power fields (HPF) at invasive front classified by mean number buds per...
BACKGROUND: Additional prognostic markers are needed for better treatment stratification of stage II colon cancer (CC). We investigated the value tumor-infiltrating lymphocytes (TILs) in a true population-based cohort patients with CC. MATERIAL AND METHODS: A total 573 were included. Tumor blocks representing deepest invasive part primary tumor used analysis. CD3+ and CD8+ TILs at front evaluated by immunohistochemistry on whole sections. The area was manually outlined, Visiopharm Integrator...
The aim of the present study was to validate prognostic impact CDX2 in patients with stage II colon cancer. Two unbiased population-based cohorts representing all operated for cancer Denmark 2002 and 2003. expression evaluated by immunohistochemistry on whole tumour sections. Patients were classified into three groups, CDX2-positive, -moderate, -negative, comparison clinical data. A total 1157 included. We found a significant relationship between loss poor disease-free survival both cohorts,...
Patients suffering from high risk stage II colon cancer (CC) may benefit adjuvant onco-therapy, but additional prognostic markers are needed for better treatment stratification. We investigated the value of Programmed Death Ligand-1 (PD-L1) in a true population-based cohort patients with CC. PD-L1 expression on tumour cells was evaluated by immunohistochemistry 572 cancers. Whole sections blocks representing deepest invasive front primary were used analysis. A cut-off 5% positivity...
Precise prognostic and predictive variables allowing improved post-operative treatment stratification are missing in patients treated for stage II colon cancer (CC). Investigation of tumor infiltrating lymphocytes (TILs) may be rewarding, but the lack a standardized analytic technique is major concern. Manual stereological counting considered gold standard, digital pathology with image analysis preferred due to time efficiency. The purpose this study was compare manual estimates TILs...
Tumour budding (TB) and Stroma Ratio (TSR) may be rewarding in the treatment stratification of patients with stage II colon cancer. However, lack standardization exclude these parameters from being used a clinical setting. The purpose this methodologic study was to compare stereology semi-quantitative estimations TSR, investigate intra-tumoural heterogeneity TB assess intra- inter-observer agreement.Three paraffin embedded tumour blocks, one them representing deepest invasive front, were...
3610 Background: The aim of the present study was to validate prognostic impact CDX2 in stage II colon cancer and confirm its clinical potential. Methods: Individual patient data formalin fixed, paraffin embedded tumor tissue were collected from two unbiased, population-based cohorts representing all patients operated for Denmark 2002 2003. expression evaluated by immunohistochemistry on whole sections. Patients classified into three groups, expression: positive, intermediate, negative,...
183 Background: Up-regulation of the transcription factor SOX9 has been described in colon cancer, and it argued that differences expression levels dictates cell proliferation. The aim present study was to analyze prognostic impact patients with stage II cancer. Methods: Individual patient data formalin fixed paraffin embedded tumor tissue were collected from a large unbiased, population-based cohort, representing all operated for cancer Denmark 2002 2003. evaluated by immunohistochemistry...
3580 Background: Patients with high-risk stage II colon cancer (CC) may benefit from adjuvant chemotherapy, but additional prognostic markers are needed for better treatment stratification. We investigated the value of tumour infiltrating lymphocytes (TILs) in a true population-based cohort patients CC. Methods: A total 573 were included, representing all operated Denmark 2002. Tumour blocks deepest invasive part primary used analysis. CD3+ and CD8+ TILs at front evaluated by...
e15165 Background: Up-regulation of the transcription factor SOX9 has been described in colon cancer, and it argued that differences expression levels dictates cell proliferation. The aim present study was to analyze prognostic impact stage II cancer. Methods: Individual patient data formalin fixed paraffin embedded tumor tissue were collected from a large unbiased, population-based cohort, representing all patients operated for cancer Denmark 2002 2003. evaluated by immunohistochemistry on...